Abstract:e15547 Background: Although PD-1 blockade has been recommended as the first line treatment in DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC), it is worthwhile to investigate whether mCRC with DNA mismatch repair-proficient/microsatellite stable(pMMR/MSS) tumors benefit from a combination treatment with PD-1 blockade. Methods: In this cohort, ten patients with pMMR/MSS colorectal liver metastases (CRLM) treated in the 6th Affiliated Hospital of Sun Yat-sen University were enrolled. All the patients were exploratively treated with at least four doses of PD-1 monoclonal antibody combined with chemotherapy and bevacizumab as neoadjuvant/adjuvant therapy. The aim of the study was to evaluate the short-term efficacy and safety of this combined strategy. Results: All the 10 patients were confirmed pMMR/MSS by IHC or next generation sequencing (NGS). Eight of the 10 patients accepted the combined therapies before primary tumor resections, disease control rate (DCR) was 100% (8/8) and objective response rate (ORR) was 62.5% (5/8). The ORR of liver metastases was 70% (7/10) after this treatment. Pathologic complete response (pCR) was achieved in one patient’s primary tumor and was also achieved in another patient’s hepatic lesion. Four patients underwent simultaneous resection of primary tumor and liver metastases. Nine patients underwent microwave ablation for liver metastases. Five patients were assessed no evidence of disease (NED) with a median progress-free survival (PFS) of 5.0 (4.2-9.9) months after multimodality treatments for both primary and metastatic lesions. No immunotherapeutic associated sever adverse event (SAE) or operational complications were found in this cohort. Conclusions: PD-1 blockade combined chemotherapy and bevacizumab was safe and effective for patients with pMMR/MSS CRLM, which might lead to better tumor regression as well as more chances of NED. Further clinical phase II studies of evaluation of long-term efficacy of this combined strategy was needed.

A new strategy for immunotherapy of microsatellite‐stable (MSS)‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD‐1/PD‐L1 inhibitors

Immunotherapy Combined with Local Therapy in the Late-Line Treatment of Repair-Proficient (pmmr)/microsatellite Stable (MSS) Metastatic Colorectal Cancer

PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies

How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC

General Treatment for Metastatic Colorectal Cancer: from KEYNOTE 177 Study.

Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?

Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies

Exploring immunotherapy in colorectal cancer

Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer

Immunotherapy in Colorectal Cancer: Current Achievements and Future Perspective

Intratumoral Injection of Interferon Gamma Promotes the Efficacy of Anti-Pd1 Treatment in Colorectal Cancer

Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer

PD-1 blockade combined with chemotherapy and bevacizumab in DNA mismatch repair-proficient/microsatellite stable colorectal liver metastases

Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies.

Efficacy and challenges of anti-PD1 in MSI-H mCRC: a case report on concurrent infections and ir-AIHA

Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions

Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer

Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report

Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy

PD-1 Blockade Combined Chemotherapy and Bevacizumab in DNA Mismatch Repair-Proficient/microsatellite Stable Colorectal Liver Metastases.

Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting